The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of nivolumab plus ipilimumab versus immune checkpoint inhibitor and tyrosine kinase inhibitor combinations as first-line treatment for metastatic clear cell renal cell carcinoma.
 
Faisal Azam
No Relationships to Disclose
 
Mubarak Almansour
No Relationships to Disclose
 
Bassam Basulaiman
Honoraria - Amgen; AstraZeneca
Travel, Accommodations, Expenses - Janssen Oncology; Roche
 
Mohamed Aseafan
No Relationships to Disclose
 
Mahmoud Elshenawy
No Relationships to Disclose
 
Tusneem Elhassan
No Relationships to Disclose
 
Ali Sheikh
No Relationships to Disclose
 
Shouki Bazarbashi
Honoraria - AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Hikma; Ipsen; Lilly; Merck Serono; Merck Sharp & Dohme; Newbridge Pharmaceuticals; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; HIKMA; Ipsen; Merck KGaA; Merck Sharp & Dohme; pfizer; Roche; Taiba
Research Funding - Astellas Pharma (Inst); Kite/Gilead (Inst); Lilly; Merck KGaA (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Hikma Pharmaceuticals; Ipsen; Janssen; Merck; SERVIER